# Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

> **NCT03734991** · PHASE3 · COMPLETED · sponsor: **Scynexis, Inc.** · enrollment: 376 (actual)

## Conditions studied

- Candida Vulvovaginitis

## Interventions

- **DRUG:** Ibrexafungerp
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03734991
- **Lead sponsor:** Scynexis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-04
- **Primary completion:** 2019-08-21
- **Final completion:** 2019-09-04
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2021-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03734991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03734991, "Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03734991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*